Vallon Pharmaceuticals will present at Q3 Virtual



Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18e 12:30 PM HEY

PHILADELPHIA, PA, Aug 11, 2021 (GLOBE NEWSWIRE) – Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs designed to deter abuse in the treatment of the central nervous system (CNS ), today announced that David Baker, President and CEO of Vallon, will be presenting at the Q3 Virtual Investor Summit on Wednesday, August 18, 2021 at 12:30 p.m. ET.

In addition to the presentation, management will be available to participate in one-on-one virtual meetings with qualified members of the investment community who have registered to attend the conference. For more information on the conference, please visit the conference website.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website ( and will be archived for 90 days following the event.

About Vallon Medications, Inc.

Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Philadelphia, Pennsylvania. The Company is focused on the development of new drugs to help patients with central nervous system (CNS) disorders. The Company’s lead product candidate, ADAIR, is a novel immediate-release amphetamine abuse deterrent formulation under development for the treatment of ADHD and narcolepsy.

For more information about the company, please visit or contact us on LinkedIn or Twitter.

References and links to websites have been provided as a convenience, and the information contained on such website does not form part of, or by reference to, this press release. Vallon is not responsible for the content of third party websites.

Investor Contact:
Jenene thomas
(833) 475-8247



Leave A Reply